SCM
ACAD icon

Stonepine Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Stonepine Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$2.39M – 84
2025
Q4 		$2.67M Sell
100,000
-74,544
-43% -$1.78M 1.95% 15
2025
Q3 		$3.72M Sell
174,544
-50,456
-22% -$1.19M 3.03% 8
2025
Q2 		$4.85M Buy
225,000
+131,607
+141% +$2.45M 4.76% 6
2025
Q1 		$186K Sell
93,393
-126,607
-58% -$2.3M 0.18% 51
2024
Q4 		$4.04M Buy
220,000
+23,105
+12% +$373K 3.26% 7
2024
Q3 		$3.03M Buy
196,895
+191,895
+3,838% +$3.2M 1.91% 17
2024
Q2 		$81.3K Buy
+5,000
New +$80.7K 0.07% 25
2018
Q3 		– Sell
-194,900
Closed -$2.98M – 32
2018
Q2 		$2.98M Buy
+194,900
New +$3.48M 1.81% 16

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stonepine Capital Management's ACAD Position: Q1 2026 in Review

Stonepine Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 100,000 shares — an estimated $2.39M sold.

Stonepine Capital Management first reported a position in ACAD in Q2 2018 and held it in 8 quarters. The position peaked at $4.85M in Q2 2025. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Stonepine Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Stonepine Capital Management sold 100,000 Acadia Pharmaceuticals shares in Q1 2026, an estimated $2.39M.
  • Stonepine Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 8 quarters.
  • Stonepine Capital Management's Acadia Pharmaceuticals position peaked at $4.85M in Q2 2025.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.